A unified spatial-molecular atlas of DCIS-IBC progression is established, highlighting clonal expansion, transcriptional plasticity and TME remodeling as key drivers of invasion.
Abstract
The progression from ductal carcinoma in situ (DCIS) to invasive breast carcinoma (IBC) critically determines patient outcomes, yet its mechanisms remain incompletely understood. Integrating single-cell RNA sequencing, spatial transcriptomics, and genomics across 28 patients with synchronous DCIS and IBC, we delineate the spatial-molecular hierarchy of this transition. Invasion is primarily driven by clonal expansion of pre-existing DCIS subclones, emphasizing transcriptional reprogramming and tumor microenvironment (TME) remodeling over acquisition of additional driver alterations. IBC cells exhibit pronounced epithelial-mesenchymal transition and metabolic reprogramming. We uncover dynamic TME remodeling at the invasive front, identifying key ligand–receptor interactions (e.g., PPIA-BSG, MDK-LRP1, CXCL12-CXCR4) facilitating basement membrane disruption, angiogenesis and immunosuppression. Deconvolution of basement membrane breach reveals four molecularly defined stages (NMFT1–NMFT4) with progressively worsening patient survival. This study establishes a unified spatial-molecular atlas of DCIS-IBC progression, highlighting clonal expansion, transcriptional plasticity and TME remodeling as key drivers of invasion. The progression from ductal carcinoma in situ (DCIS) to invasive breast carcinoma (IBC) is not fully understood yet. Here, the authors integrate single-cell RNA-seq, spatial transcriptomics, and genomics data from patients with synchronous DCIS and IBC; they find clonal expansion, transcriptional plasticity, and tumour microenvironment remodelling as key drivers of DCIS-IBC progression.
This study defines a spatially organized, functionally coordinated multicellular niche that drives ICB resistance in ccRCC, establishing both a predictive biomarker for patient stratification and a mechanistic framework for therapeutic intervention.
It is suggested that integrated single-cell and spatial transcriptomics offers transformative potential to advance precision oncology and improve outcomes for patients with pancreatic cancer.
Mengting Luo, Feng Shen, Wanli Xu et al.· Cancer Biology & Therapy· 0 citations
Findings support a model in which progression-relevant breast tissue remodeling may begin at the DH stage and nominate cellular states and candidate biomarkers for prospective validation in breast cancer risk stratification among patients with DH.
Siwei Ju, Zhanzhi Li, Li-Dan Jin et al.· bioRxiv· 0 citations
The uncovered molecular signatures offered mechanistic clues linking EMT, hormone resistance, and local immune status during lesion evolution and preliminary molecular evidence to support pathological stratification and targeted precision therapeutic strategies for PCa was provided.
Recent discoveries from single-cell and spatial analyses are summarized, their implications for biomarker development and treatment stratification are discussed, and ongoing technical challenges are outlined, including standardization, reproducibility, and clinical scalability.
R. Watanabe, T. Chu, N. Miura et al.· American journal of clinical...· 2 citations
Breast cancer is a heterogeneous disease in which a single oncogenic driver can give rise to divergent tumor phenotypes. How oncogenic mutations generate epithelial state plasticity and coordinately remodel the surrounding tissue remains incompletely understood. Here, we applied longitudinal single cell RNA-sequencing...
Jennifer T. Le, Eun K. Kim, Vasudha Srivastava et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.